Correlation of circulating CD133+ progenitor subclasses with a mild phenotype in duchenne muscular dystrophy patients

Chiara Marchesi, Marzia Belicchi, Mirella Meregalli, Andrea Farini, Alessandra Cattaneo, Daniele Parolini, Manuela Gavina, Laura Porretti, Maria Grazia D'Angelo, Nereo Bresolin, Giulio Cossu, Yvan Torrente

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Various prognostic serum and cellular markers have been identified for many diseases, such as cardiovascular diseases and tumor pathologies. Here we assessed whether the levels of certain stem cells may predict the progression of Duchenne muscular dystrophy (DMD). Methods and Findings: The levels of several subpopulations of circulating stem cells expressing the CD133 antigen were determined by flow cytometry in 70 DMD patients. The correlation between the levels and clinical status was assessed by statistical analysis. The median (±SD) age of the population was 10.66±3.81 (range 3 to 20 years). The levels of CD133+CXCR4+CD34- stem cells were significantly higher in DMD patients compared to healthy controls (mean±standard deviation: 17.38±1.38 vs 11.0±1.70; P = 0.03) with a tendency towards decreased levels in older patients. Moreover, the levels of this subpopulation of cells correlated with the clinical condition. In a subgroup of 19 DMD patients after 24 months of follow-up, increased levels of CD133+CXCR4+CD34- cells was shown to be associated with a phenotype characterised by slower disease progression. The circulating CD133+CXCR4+CD34- cells in patients from different ages did not exhibit significant differences in their myogenic and endothelial in vitro differentiation capacity. Conclusions: Our results suggest that levels of CD133+CXCR4+CD34- could function as a new prognostic clinical marker for the progression of DMD.

Original languageEnglish
Article numbere2218
JournalPLoS One
Volume3
Issue number5
DOIs
Publication statusPublished - May 21 2008

Fingerprint

muscular dystrophy
Duchenne Muscular Dystrophy
Stem cells
Phenotype
phenotype
stem cells
Stem Cells
Flow cytometry
Pathology
Biomarkers
Tumors
Statistical methods
Cells
Antigens
cells
disease course
cardiovascular diseases
flow cytometry
Disease Progression
Flow Cytometry

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Correlation of circulating CD133+ progenitor subclasses with a mild phenotype in duchenne muscular dystrophy patients. / Marchesi, Chiara; Belicchi, Marzia; Meregalli, Mirella; Farini, Andrea; Cattaneo, Alessandra; Parolini, Daniele; Gavina, Manuela; Porretti, Laura; D'Angelo, Maria Grazia; Bresolin, Nereo; Cossu, Giulio; Torrente, Yvan.

In: PLoS One, Vol. 3, No. 5, e2218, 21.05.2008.

Research output: Contribution to journalArticle

@article{db3369ef228d461c9874520c4dfa83e7,
title = "Correlation of circulating CD133+ progenitor subclasses with a mild phenotype in duchenne muscular dystrophy patients",
abstract = "Background: Various prognostic serum and cellular markers have been identified for many diseases, such as cardiovascular diseases and tumor pathologies. Here we assessed whether the levels of certain stem cells may predict the progression of Duchenne muscular dystrophy (DMD). Methods and Findings: The levels of several subpopulations of circulating stem cells expressing the CD133 antigen were determined by flow cytometry in 70 DMD patients. The correlation between the levels and clinical status was assessed by statistical analysis. The median (±SD) age of the population was 10.66±3.81 (range 3 to 20 years). The levels of CD133+CXCR4+CD34- stem cells were significantly higher in DMD patients compared to healthy controls (mean±standard deviation: 17.38±1.38 vs 11.0±1.70; P = 0.03) with a tendency towards decreased levels in older patients. Moreover, the levels of this subpopulation of cells correlated with the clinical condition. In a subgroup of 19 DMD patients after 24 months of follow-up, increased levels of CD133+CXCR4+CD34- cells was shown to be associated with a phenotype characterised by slower disease progression. The circulating CD133+CXCR4+CD34- cells in patients from different ages did not exhibit significant differences in their myogenic and endothelial in vitro differentiation capacity. Conclusions: Our results suggest that levels of CD133+CXCR4+CD34- could function as a new prognostic clinical marker for the progression of DMD.",
author = "Chiara Marchesi and Marzia Belicchi and Mirella Meregalli and Andrea Farini and Alessandra Cattaneo and Daniele Parolini and Manuela Gavina and Laura Porretti and D'Angelo, {Maria Grazia} and Nereo Bresolin and Giulio Cossu and Yvan Torrente",
year = "2008",
month = "5",
day = "21",
doi = "10.1371/journal.pone.0002218",
language = "English",
volume = "3",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - Correlation of circulating CD133+ progenitor subclasses with a mild phenotype in duchenne muscular dystrophy patients

AU - Marchesi, Chiara

AU - Belicchi, Marzia

AU - Meregalli, Mirella

AU - Farini, Andrea

AU - Cattaneo, Alessandra

AU - Parolini, Daniele

AU - Gavina, Manuela

AU - Porretti, Laura

AU - D'Angelo, Maria Grazia

AU - Bresolin, Nereo

AU - Cossu, Giulio

AU - Torrente, Yvan

PY - 2008/5/21

Y1 - 2008/5/21

N2 - Background: Various prognostic serum and cellular markers have been identified for many diseases, such as cardiovascular diseases and tumor pathologies. Here we assessed whether the levels of certain stem cells may predict the progression of Duchenne muscular dystrophy (DMD). Methods and Findings: The levels of several subpopulations of circulating stem cells expressing the CD133 antigen were determined by flow cytometry in 70 DMD patients. The correlation between the levels and clinical status was assessed by statistical analysis. The median (±SD) age of the population was 10.66±3.81 (range 3 to 20 years). The levels of CD133+CXCR4+CD34- stem cells were significantly higher in DMD patients compared to healthy controls (mean±standard deviation: 17.38±1.38 vs 11.0±1.70; P = 0.03) with a tendency towards decreased levels in older patients. Moreover, the levels of this subpopulation of cells correlated with the clinical condition. In a subgroup of 19 DMD patients after 24 months of follow-up, increased levels of CD133+CXCR4+CD34- cells was shown to be associated with a phenotype characterised by slower disease progression. The circulating CD133+CXCR4+CD34- cells in patients from different ages did not exhibit significant differences in their myogenic and endothelial in vitro differentiation capacity. Conclusions: Our results suggest that levels of CD133+CXCR4+CD34- could function as a new prognostic clinical marker for the progression of DMD.

AB - Background: Various prognostic serum and cellular markers have been identified for many diseases, such as cardiovascular diseases and tumor pathologies. Here we assessed whether the levels of certain stem cells may predict the progression of Duchenne muscular dystrophy (DMD). Methods and Findings: The levels of several subpopulations of circulating stem cells expressing the CD133 antigen were determined by flow cytometry in 70 DMD patients. The correlation between the levels and clinical status was assessed by statistical analysis. The median (±SD) age of the population was 10.66±3.81 (range 3 to 20 years). The levels of CD133+CXCR4+CD34- stem cells were significantly higher in DMD patients compared to healthy controls (mean±standard deviation: 17.38±1.38 vs 11.0±1.70; P = 0.03) with a tendency towards decreased levels in older patients. Moreover, the levels of this subpopulation of cells correlated with the clinical condition. In a subgroup of 19 DMD patients after 24 months of follow-up, increased levels of CD133+CXCR4+CD34- cells was shown to be associated with a phenotype characterised by slower disease progression. The circulating CD133+CXCR4+CD34- cells in patients from different ages did not exhibit significant differences in their myogenic and endothelial in vitro differentiation capacity. Conclusions: Our results suggest that levels of CD133+CXCR4+CD34- could function as a new prognostic clinical marker for the progression of DMD.

UR - http://www.scopus.com/inward/record.url?scp=48249142812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48249142812&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0002218

DO - 10.1371/journal.pone.0002218

M3 - Article

VL - 3

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e2218

ER -